Pacific Biosciences Of California, Inc. shares rise 1.56% premarket after FDA approved breakthrough therapies for aggressive malignancies.

Pacific Biosciences Of California, Inc. rose 1.56% in premarket trading. The company's stock price increase may be attributed to the recent regulatory momentum in the cancer treatment sector, as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain tumors. This regulatory support is generating substantial opportunities for companies with cutting-edge oncology platforms to leverage expedited approval pathways.